Artelo Biosciences Enters Into Global R&D Partnership With Syngene International And Aptus Clinical For The Clinical Development Of ART27.13 In Oncology
Cision PR Newswire- 12/06/2018. As part of the agreement, Syngene will be the discovery and development partner providing a pre-clinical data package to support the advancement of ART27.13 for anti-cancer indications.
Syngene teams with immuno-oncology firm to provide greater value-added services
Out Sourcing Pharma- 04/06/2018. As per the partnering agreement, Syngene will screen target antigens Zumutor’s human antibody libraries to identify and characterize novel antibody clones- which it will further develop towards novel biotherapeutics programs.